PLoS ONE (Jan 2020)

Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma.

  • Yukie Suzuki,
  • Tatsuyuki Takadate,
  • Masamichi Mizuma,
  • Hiroki Shima,
  • Takashi Suzuki,
  • Tomoyoshi Tachibana,
  • Mitsuhiro Shimura,
  • Tatsuo Hata,
  • Masahiro Iseki,
  • Kei Kawaguchi,
  • Takeshi Aoki,
  • Hiroki Hayashi,
  • Takanori Morikawa,
  • Kei Nakagawa,
  • Fuyuhiko Motoi,
  • Takeshi Naitoh,
  • Kazuhiko Igarashi,
  • Michiaki Unno

DOI
https://doi.org/10.1371/journal.pone.0235904
Journal volume & issue
Vol. 15, no. 7
p. e0235904

Abstract

Read online

Pancreatic ductal adenocarcinoma is one of the most aggressive types of cancer. Certain proteins in the tumor microenvironment have attracted considerable attention owing to their association with tumor invasion and metastasis. Here, we used proteomics to identify proteins associated with lymph-node metastasis, which is one of the prognostic factors. We selected lymph node metastasis-positive and -negative patients (n = 5 each) who underwent pancreatectomy between 2005 and 2015 and subjected to comprehensive proteomic profiling of tumor stroma. A total of 490 proteins were detected by mass spectrometry. Software analysis revealed that nine of these proteins were differentially expressed between the two patient groups. We focused on hemopexin and ferritin light chain based on immunohistochemistry results. We assessed the clinicopathological data of 163 patients and found that hemopexin expression was associated with UICC N2 (p = 0.0399), lymph node ratio (p = 0.0252), venous invasion (p = 0.0096), and lymphatic invasion (p = 0.0232). Notably, in vitro assays showed that hemopexin promotes invasion of the pancreatic cancer cells. Our findings suggest that hemopexin is a lymph node metastasis-associated protein that could potentially serve as a useful therapeutic target or biomarker of pancreatic ductal adenocarcinoma.